Target Name: ANKRD35
NCBI ID: G148741
Other Name(s): Ankyrin repeat domain 35, transcript variant 1 | ANKRD35 variant 2 | Ankyrin repeat domain 35, transcript variant 2 | Ankyrin repeat domain-containing protein 35 (isoform 1) | FLJ25124 | MGC126669 | ANKRD35 variant 1 | Ankyrin repeat domain protein 35 | ankyrin repeat domain 35 | MGC126667 | ankyrin repeat domain-containing protein 35-like | Ankyrin repeat domain-containing protein 35 | ANR35_HUMAN | Ankyrin repeat domain-containing protein 35 (isoform 2)

ANKRD35: A Potential Drug Target and Biomarker

Ankyrin repeat domain 35 (ANKRD35) is a gene that has been identified as a potential drug target and biomarker for various diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders. ANKRD35 is a member of the ankyrin gene family, which is characterized by the presence of a unique N-terminal repeat sequence. ANKRD35 has four exons, and its corresponding protein has 159 amino acid residues.

The ANKRD35 gene is expressed in various tissues and organs, including brain, heart, kidneys, and pancreas. It is also highly expressed in the placenta, which suggests that it may be involved in fetal development and growth.

The ANKRD35 protein is involved in various cellular processes, including cell signaling, protein synthesis, and intracellular transport. It is a protein that is involved in the regulation of the actinin protein, which is a critical protein for cell signaling.

In addition to its role in cellular signaling, ANKRD35 is also a potential drug target. Its unique N-terminal repeat sequence has been shown to be involved in protein-protein interactions, which may make it a useful target for small molecules. In addition, ANKRD35 has been shown to be involved in the regulation of cellular processes that are related to disease, such as inflammation and fibrosis.

As a potential drug target, ANKRD35 is being investigated for its potential utility in treating various diseases, including cardiovascular disease, diabetes, and neurodegenerative disorders. For example, studies have shown that ANKRD35 is involved in the regulation of cellular processes that are related to the development and progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

In addition to its potential use as a drug target, ANKRD35 is also being investigated as a biomarker for various diseases. Its unique N-terminal repeat sequence has been shown to be involved in the regulation of cellular processes that are related to disease, such as inflammation and fibrosis. This suggests that ANKRD35 may be a useful biomarker for diseases that are characterized by inflammation or fibrosis.

In conclusion, ANKRD35 is a gene that has been identified as a potential drug target and biomarker for various diseases. Its unique N-terminal repeat sequence and its involvement in cellular processes that are related to disease make it a promising target for small molecules. Further research is needed to determine its full potential as a drug and biomarker.

Protein Name: Ankyrin Repeat Domain 35

More Common Targets

ANKRD36 | ANKRD36B | ANKRD36BP1 | ANKRD36BP2 | ANKRD36C | ANKRD37 | ANKRD39 | ANKRD40 | ANKRD40CL | ANKRD42 | ANKRD44 | ANKRD45 | ANKRD46 | ANKRD49 | ANKRD50 | ANKRD52 | ANKRD53 | ANKRD54 | ANKRD55 | ANKRD6 | ANKRD60 | ANKRD61 | ANKRD62 | ANKRD63 | ANKRD65 | ANKRD65-AS1 | ANKRD66 | ANKRD7 | ANKRD9 | ANKS1A | ANKS1B | ANKS3 | ANKS4B | ANKS6 | ANKUB1 | ANKZF1 | ANLN | Annexin | ANO1 | ANO10 | ANO2 | ANO3 | ANO4 | ANO5 | ANO6 | ANO7 | ANO7L1 | ANO8 | ANO9 | Anoctamin | ANOS1 | ANOS2P | ANP32A | ANP32A-IT1 | ANP32AP1 | ANP32B | ANP32C | ANP32D | ANP32E | ANPEP | ANTKMT | ANTXR1 | ANTXR2 | ANTXRL | ANTXRLP1 | ANXA1 | ANXA10 | ANXA11 | ANXA13 | ANXA2 | ANXA2P1 | ANXA2P2 | ANXA2P3 | ANXA2R | ANXA2R-AS1 | ANXA2R-OT1 | ANXA3 | ANXA4 | ANXA5 | ANXA6 | ANXA7 | ANXA8 | ANXA8L1 | ANXA8L2 | ANXA9 | AOAH | AOC1 | AOC2 | AOC3 | AOC4P | AOPEP | AOX1 | AOX2P | AP-1 Transcription Factor Complex | AP1AR | AP1B1 | AP1B1P1 | AP1G1 | AP1G2 | AP1M1